ReviewClinical rheumatology2026
Overlapping autoimmunity and demyelination syndromes associated with TNF inhibitor therapy.
Review in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating disorder of the central nervous system. We describe a case of a 31-year-old male with ankylosing spondylitis who developed optic neuritis and transverse myelitis accompanied by positive anti-MOG antibodies, and subsequently features consistent with systemic lupus erythematosus (SLE), beginning 3 months after initiating adalimumab. Adalimumab was discontinued, and the patient was treated with pulsed intravenous methylprednisolone followed by rituximab with significant improvement in clinical, imaging, and laboratory manifestations of the disease. This case highlights a rare constellation of overlapping autoimmune diseases, with both MOGAD and SLE emerging after anti-TNF antibody exposure in a patient with ankylosing spondylitis.
Indexed as
Identifiers
41652144What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.